van Os J, Schraffordt Koops H, Oldhoff J
Cancer. 1985 Feb 15;55(4):698-701. doi: 10.1002/1097-0142(19850215)55:4<698::aid-cncr2820550404>3.0.co;2-2.
During the period from February to October 1983, 21 patients with malignant melanoma of the extremities were treated by hyperthermic regional isolated perfusion with L-phenylalanine mustard (melphalan). The melphalan dose for each patient was determined by the tissue volume of the perfused region, using a dose of 10 mg/l perfused tissue. Despite an average increase of melphalan dosage of 18% above the maximum for iliac perfusions recommended in the literature, no increase in toxic tissue reactions was observed after hyperthermic iliac perfusions. The same dose of 10 mg/l perfused tissue was used in hyperthermic axillary perfusions, resulting in an average decrease of melphalan dosage of 14% below the minimum recommended in the literature. By applying a constant dose per unit tissue volume, a standardization of treatment is achieved. This excludes variations like body weight, age, type of complexion, and hair color, which so far have determined dosimetry.
1983年2月至10月期间，对21例四肢恶性黑色素瘤患者采用左旋苯丙氨酸氮芥（美法仑）进行高温区域隔离灌注治疗。每位患者的美法仑剂量根据灌注区域的组织体积确定，采用10 mg/l灌注组织的剂量。尽管美法仑剂量平均比文献中推荐的髂骨灌注最大剂量高出18%，但高温髂骨灌注后未观察到毒性组织反应增加。高温腋窝灌注采用相同的10 mg/l灌注组织剂量，导致美法仑剂量平均比文献中推荐的最小剂量低14%。通过应用每单位组织体积的恒定剂量，实现了治疗的标准化。这排除了体重、年龄、肤色类型和发色等因素的变化，这些因素迄今为止一直决定着剂量测定。
